New CEO at Morningside as Nik Kotecha becomes chairman

7 October 2020

morningside-chairman-dr-nik-kotecha-ceo-tim-brady

UK-based medicines manufacturer and supplier Morningside Pharmaceuticals has appointed a new chief executive, with previous CEO Nik Kotecha (pictured above, right, with Tim Brady) to take on a strategic role and become chairman of the board.

The executive team and group board will be responsible for enhancing internal and external systems and processes, as well as delivering the business’ ambitious growth plans for the future.

Tim Brady, who has extensive experience of leading business development and sales and marketing in the pharmaceuticals’ sector, has become the business’ new CEO. He joins newly-appointed chief operating officer Monica Huang and chief financial officer Cliff Fung as leader of the company’s executive team.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK